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ABSTRACT
Despite widespread adoption of disease management (DM) programs by US health plans,
gaps remain in the evidence for their benefit. The Disease Management Outcomes Consoli-
dation Survey was designed to gather data on DM programs for commercial health plans, to
assess program success and DM effectiveness. The questionnaire was mailed to 292 appro-
priate health plan contacts; 26 plans covering more than 14 million commercial members com-
pleted and returned the survey. Respondents reported that DM plays a significant and in-
creasing role in their organizations. Key reasons for adopting DM were improving clinical
outcomes, reducing medical costs and utilization, and improving member satisfaction. More
respondents were highly satisfied with clinical results than with utilization or cost outcomes
of their programs (46%, 17%, and 13%, respectively). Detailed results were analyzed for 57
DM programs with over 230,000 enrollees. Most responding plans offered DM programs for
diabetes and asthma, with return on investment (ROI) ranging from 0.16:1 to 4:1. Weighted
by number of enrollees per DM program, average ROI was 2.56:1 for asthma (n  1,136 en-
rollees) and 1.98:1 for diabetes (n  25,364). Most (but not all) respondents reported reduced
hospital admissions, increasing rates of preventive care, and improved clinical measures. Few
respondents provided detailed information about DM programs for other medical conditions,
but most that did reported positive outcomes. Lack of standardized methodology was iden-
tified as a major barrier to in-house program evaluation. Although low response rate pre-
cluded drawing many general conclusions, a clear need emerged for more rigorous evalua-




DISEASE MANAGEMENT (DM) programs arecoordinated health care interventions for
medical conditions in which patient self-care
behaviors can play an important role.1 Specific
populations are identified for enrollment in
programs in which patients are monitored for
deviations from evidence-based care or symp-
toms indicative of worsening health.2 DM 
1Disease Management Association of America, Washington, D.C.
2Thomson Medstat, Ann Arbor, Michigan.
3BioMedCom Consultants inc., Montreal, QC, Canada.
4Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California.
programs aim to prevent exacerbations and
complications by contacting patients and some-
times their physicians to provide support (eg,
self-management education) to improve pa-
tient self-management skills.1,2
In addition to improving clinical outcomes
and patient quality of life, an objective of DM
programs of great importance to health plans
and employers is to improve health care qual-
ity and control costs, for example by avoiding
hospitalization.2 Although positive clinical out-
comes of DM programs have been demon-
strated in several studies,3 the economic bene-
fit and financial return on investment (ROI) of
DM programs have been challenged. On the
basis of an analysis of the peer-reviewed liter-
ature of DM programs for congestive heart fail-
ure (CHF), coronary artery disease (CAD) and
diabetes, the US Congressional Budget Office
(CBO) reported in October 2004 that there was
insufficient evidence to conclude that DM pro-
grams reduce overall health care costs.4 Al-
though the research methodology employed by
the CBO to reach this conclusion has been ques-
tioned,5 another recent systematic literature re-
view also found few studies had demonstrated
significant cost savings for DM programs.3
The databases of commercial health plans that
offer DM programs could help to fill the infor-
mation gap on financial outcomes. Many DM
programs are proprietary, and it has been sug-
gested that more is known about costs for DM
programs than has been published or released
into the public domain.6 Furthermore, commer-
cial health care organizations possess a wealth of
other data on clinical and utilization outcomes,
which could provide a more comprehensive un-
derstanding of the value of DM programs.
To capture information from health plans and
other sources about DM programs and their
outcomes, in 2004 the Disease Management As-
sociation of America (DMAA) launched the
Disease Management Outcomes Consolidation
Project. Components of the project were a com-
prehensive catalog of the published literature
and unpublished reports,7 and a survey of
health plans providing DM programs to com-
mercial members, conducted by a qualified in-
dependent contractor (Medstat). The objectives
of the survey were to allow comparison of re-
sults between different programs, and to serve
as a resource for DMAA and its members to re-
spond to government agencies, employers, and
others who request evidence of the effectiveness
of DM. Survey results are potentially valuable
because they capture the experience of experts
in commercial health plans who may not nor-




The Outcomes Consolidation Survey instru-
ment was designed to record descriptions of
health plan DM programs and associated clin-
ical and economic outcomes. A preliminary
Web-based version of the survey (DMAA Out-
comes Collection Survey) was designed by the
DMAA Quality and Research Committee and
pilot-tested in 2003, targeting private US health
insurance plans. This pilot survey was com-
pleted by 27 respondents with responsibility
for DM program development or implementa-
tion within their organizations. The pilot sur-
vey requested details of DM program devel-
opment, operational components, enrollment,
longevity and outcomes. Additional items
asked health plans to identify their rationale for
offering DM programs, future program devel-
opment priorities, barriers to program expan-
sion, and use of the Internet. Respondents also
rated their satisfaction with DM programs, the
success of specific program components, and
the importance of their DM programs to cur-
rent and prospective customers. In collabora-
tion with the DMAA Quality and Research
Committee and the DMAA Outcomes Consol-
idation Steering Committee, Medstat used re-
sults of the 2003 pilot survey to refine the ques-
tionnaire. A revised version was sent to five
health plans for pilot-testing, three of which re-
sponded. The survey was subsequently evalu-
ated and refined by a Delphi panel of 15 na-
tional experts before production of the final
version for the 2004 study.
The Outcomes Consolidation Survey instru-
ment was distributed and returned by mail. The
survey consisted of the following eight sections:
organization description; DM approach; current
DM programs for commercial members; DM
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program tools; DM program outcomes over-
view (a general assessment of program success);
specific results from DM evaluations; DM pro-
grams and employer customers; and future
planning for DM. Specific questions in each sec-
tion are described in Results.
Responses were elicited in different ways
due to the diverse nature of the topics. Ques-
tions required either Yes/No answers, numer-
ical responses, ranking of a series of items, or
selection of a grade on a four- or five-point Lik-
ert scale. Likert scales were anchored at ex-
tremes such as “strongly agree” and “strongly
disagree,” or “unimportant” and “very impor-
tant.” One five-part question regarding specific
results from DM evaluations required free-
form text responses.
Subjects
The Outcomes Consolidation Survey targeted
US health plans covering commercial members.
Directors of Disease Management were the pre-
ferred contacts within each plan, followed by
Chief Executive Officers or Chief Medical Offi-
cers. Respondents were requested to consider in
their responses all enrollees for whom their plan
was the primary health care payer, which could
potentially include some Medicare-eligible
members over age 65 years. National plans of-
fering multiple DM programs in different loca-
tions were invited to request additional copies
of the survey to complete for different locations
(eg, on a state-by-state basis).
The survey was mailed by DMAA on July 1,
2004 to 702 health plan contacts compiled from a
list of 90 DMAA members, 41 Medstat contacts,
and an additional 571 contacts from the Managed
Care Directory (Dorland Healthcare Informa-
tion). The list was processed to prevent duplica-
tion and ensure that only one contact per orga-
nization was targeted. Reminder postcards were
sent to all contacts two weeks later. Twenty-two
surveys were returned as undeliverable. A re-
search assistant subsequently attempted to con-
tact all survey recipients by telephone, and de-
termined that 410 contacts were either inaccurate
or inappropriate (eg, dental plans). The remain-
ing 292 recipients were offered free registration
at the DMAA Disease Management Leadership
Forum as incentive to complete and return the
survey. Electronic copies of the survey were e-
mailed to those recipients who requested them.
Respondents returned completed, blinded sur-
veys by mail to Medstat. Survey results were
identified by unique identification number only
to preserve respondent confidentiality. To permit
follow-up, the survey included a coded identifi-
cation sheet to be mailed to DMAA, but no one
individual could see both the survey results and
the contact names.
Disease Management Outcomes Database
Results of the Outcomes Consolidation Sur-
vey were processed by Medstat using a propri-
etary data entry and analysis tool. This database
was designed to catalog information based on
published literature, presentations and surveys
completed by health plans, and stratified by
medical condition and program operation (ie,
in-house or outsourced). For the Outcomes Con-
solidation Survey results, the database recorded
the research design and measures used by re-
sponding health plans to determine outcomes
such as changes in clinical results, member sat-
isfaction and financial outcomes.
Statistical analysis
Survey data were verified, aggregated in the
Disease Management Outcomes Database, and
analyzed to obtain summary statistics (per-
centages of respondents and means of numer-
ical responses). Because this was a descriptive
survey, no tests of statistical significance were
performed. Missing responses were not im-
puted; instead, sample sizes were adjusted on
a question-by-question basis when calculating
summary statistics to account for missing re-
sponses. Respondents were not contacted for
answers to missing items. Surveys were not ex-
cluded based on a threshold of acceptable miss-
ing data. DM program outcomes are reported
in depth only for medical conditions with de-
tailed responses from at least 10 health plans.
RESULTS
Survey respondent characteristics
Of the 292 appropriate health plan contacts
who received the Outcomes Consolidation Sur-
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vey, 28 (9.6%) completed and returned it. Two
respondents did not indicate that they covered
commercial members, and were excluded from
further analysis. Of the remaining 26 respon-
dents, 24 specified how many members (com-
mercial or otherwise) were covered by their 
organizations and two did not answer this
question. For the 24 respondents who did an-
swer this question the average number of total
health plan members was 666,459. Eighteen of
the 25 respondents (72%) who specified the
number of commercial enrollees covered by
health maintenance organization (HMO), pre-
ferred provider organization/point-of-service
(PPO/POS) or other (eg, indemnity) plans in-
dicated that their organizations covered com-
mercial members in more than one type of plan.
A slim majority (51%) of the 14,069,792 re-
ported commercial members were covered by
PPO/POS plans, with 40% covered by HMO
plans and 9% by other, unspecified plans. The
average number of commercial members per
plan was 266,959, 361,839, and 87,634 (medians:
106,904, 59,800, and 77,827) for HMO (n  21),
PPO/POS (n  20), and other plans (n  14),
respectively. Only two respondents (8%) indi-
cated that their survey responses applied to a
portion (eg, a state) of a large national health
care plan.
The importance of disease management
All but one of the 26 respondents reported
that DM plays a significant role in their orga-
nizations, with seven (27%) agreeing and 18
(69%) strongly agreeing with this statement.
The lone exception was “undecided” whether
DM plays a significant role in their organiza-
tion (the two other possible responses were dis-
agree and strongly disagree). One respondent
did not answer a question asking how their as-
sessment of DM importance compared to two
years ago; of the remaining 25, 18 (72%) said it
was a much more important strategy today,
five (20%) said it was somewhat more impor-
tant, and two (8%) said there was no change in
its importance (other response options were
somewhat less important and much less im-
portant).
Respondents were asked to rate the impor-
tance of a number of potential benefits of DM
programs to their organization’s decision to
implement DM programs, and were explicitly
told that their organization did not have to
have demonstrated achievements of these ben-
efits. All 26 respondents considered improving
clinical outcomes and reducing medical costs
to be either important or very important (Fig.
1). Reducing utilization and improving mem-
ber satisfaction were rated as important or very
important by 23 respondents (88%), and sup-
porting marketing to employer customers was
considered important or very important by 22
(85%). Supporting accreditation and improving
provider relations received more ratings of
moderate or lesser importance.
A separate item on the questionnaire asked
respondents to rate the importance of their DM
programs to their current and prospective em-
ployer customers. Of the 24 respondents who
answered this question, nine (38%) reported
that DM programs were very important, 13
(54%) important, and two (8%) somewhat im-
portant. No respondents considered their DM
programs unimportant or somewhat unimpor-
tant to prospective customers.
When asked how often customers had re-
quested proof (such as statistically sound out-
comes data) that DM is providing a positive im-
pact on productivity and absenteeism, eight of
25 respondents (32%) replied that customers of-
ten requested proof, 13 (52%) occasionally, and
four (16%) never.
Satisfaction with disease management outcomes
When asked how many discrete DM evalu-
ations their organizations had conducted since
1998, respondents reported a range of 0 to 100
evaluations (mean 8.8). Four respondents (15%)
reported conducting no evaluations; two of
these did not answer questions about their
overall satisfactions with DM program results.
For the 24 respondents who rated the satisfac-
tion of their organizations with DM program
results, 75%, 71%, and 58% were satisfied or
highly satisfied with clinical results, economic
results (eg, utilization changes), and financial
results (eg, cost savings), respectively (Fig. 2).
More respondents were highly satisfied with
clinical results (46%) than with economic (17%)
or financial (13%) results.
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All 26 respondents answered a question re-
garding how much eight potential barriers 
had impeded DM program evaluation efforts
(Table 1). The three barriers most often cited
as having some or considerable impact on
program evaluation were time (65% of re-
sponses), lack of standardized methodology
(62%), and lack of data (58%). The three bar-
riers most frequently identified as having no
or limited impact were lack of standardized
definitions (62%), lack of staff experience
(50%), and insufficient organizational prior-
ity (46%). In addition to the eight barriers
listed on the questionnaire, one respondent
wrote that lack of direct contact with mem-
bers had considerable impact on program
evaluation; another wrote that lack of ade-
quate staff and easy-to-use tools had consid-
erable impact.
Detailed results of disease management programs
Twenty-two respondents provided answers
to detailed questions about DM programs for
specific medical conditions. Each respondent
gave results for one to six individual programs
(mean 2.7). The questionnaire listed 15 condi-
tions, and respondents could specify others. No
respondents gave detailed information about
DM programs for the five following conditions
listed in the questionnaire: chronic kidney dis-
ease, HIV/AIDS, arthritis, lower back pain, and
stroke. Table 2 shows summary statistics for the
patient populations targeted and enrolled in
DM programs for the 10 other listed conditions,
plus two specified by respondents.
The method of program evaluation was iden-
tified for 52 of the programs considered. The
most common evaluation method, used for 26




















FIG. 1. Importance of potential benefits of disease management (DM) programs to health plan decisions to imple-
ment DM programs.
programs (50%), was pre-test/post-test, com-
paring outcomes for the same members from a
previous time period. Comparison of cases and
a matched historical control group (different
individuals) was used for 16 programs (31%);
nine programs (17%) used expected costs cal-
culated from an unmanaged historical control
group. Only one program (for rare diseases)
was evaluated using a randomized control
group, and no programs used a control group
of members who had opted out of the program.
Diabetes. The medical condition with the
highest number of DM programs in this survey
was diabetes, reported by all 26 respondents.
Of the 26 diabetes programs, 16 (62%) were pri-
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TABLE 1. IMPACT OF POTENTIAL BARRIERS TO DISEASE MANAGEMENT PROGRAM EVALUATION EFFORTS
Number (%a) of respondents
Barrier No impact Limited impact Some impact Considerable impact
Lack of data 7 (27) 4 (15) 9 (35) 6 (23)
Information system 6 (24) 5 (20) 11 (44) 3 (12)
Lack of standardized definitions 9 (35) 7 (27) 8 (31) 2 (8)0
Lack of standardized methodology 5 (19) 5 (19) 12 (46) 4 (15)
Lack of staff expertise 7 (27) 6 (23) 10 (38) 3 (12)
Time 5 (19) 4 (15) 10 (38) 7 (27)
Insufficient organizational priority 8 (31) 4 (15) 8 (31) 6 (23)
Cost 5 (20) 6 (24) 7 (28) 7 (28)
aPercent of responses for each barrier. n  25 for Information System and Cost, n  26 for all others.
FIG. 2. Satisfaction of health plans with clinical, economic (eg, utilization changes) and financial (eg, cost savings)
results of disease management (DM) programs.
marily built in-house, seven (27%) were out-
sourced, and three (12%) were assembled us-
ing a combination of outsourced tools and in-
house capabilities. For the 19 respondents who
specified how long their diabetes programs
had been in operation, the average duration
was 48 months.
Three respondents indicated ROI for dia-
betes DM programs of 0.16:1 (n  864 enrolled
members), 2:1 (n  24,000), and 4:1 (n  500).
Weighted by the number of enrollees per plan,
the mean ROI was 1.98:1. Eleven respondents
gave other summaries of the financial out-
comes of their diabetes DM programs, most
commonly on a cost per member per month
(PMPM) basis. Three diabetes DM programs
achieved savings, six experienced increased
costs, and two showed no change.
Respondents also provided information on
utilization outcomes. Seven reported lower
hospitalization rates for enrollees; for the five
respondents who specified a percentage de-
crease, admissions declined between 5% and
37%. However, the program with ROI of 0.16:1
experienced a 35.4% increase in inpatient ad-
missions and a 14.8% increase in emergency
room (ER) visits. Four respondents reported
fewer ER visits, of whom two provided quan-
titative results (reductions of 11% and 27%).
Three respondents found no change in ER vis-
its. Another respondent reported that inpatient
admissions for all members with diabetes de-
creased by 266 per 1000 patients, and ER visits
by 46 per 1000 over a 12-month period (n 
14,609 enrolled members).
Clinical outcomes of diabetes DM programs
were reported by 13 respondents. These results
were characterized by increasing screening
rates (seven respondents) and improved clini-
cal measures of blood glucose and lipid control
(11 respondents). In addition, four respondents
reported various measures of effect of their di-
abetes DM programs on relations with pro-
viders, indicative of high or increased provider
satisfaction.
Asthma. After diabetes, asthma was the most
frequently cited medical condition for DM pro-
grams. Twenty-three respondents offered ac-
tive asthma programs: 15 developed in-house,
six outsourced, and two assembled from in-
house and outsourced components. The aver-
age duration of asthma DM programs was 38
months for the 18 respondents who reported
how long their program had been in operation.
Two respondents specified an ROI for their
asthma program (2.5:1 and 3.5:1; n  1071
and 65 enrollees, respectively). Weighted by
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TABLE 2. STUDY POPULATION ESTIMATES FOR DISEASE MANAGEMENT PROGRAMS FOR SPECIFIC MEDICAL CONDITIONS
Mean (n responses)
Number of Members identified Members targeted for Members actively
programs with condition enrollment enrolled
Asthma 12 7,894 (12) 4,955 (12) 3,933 (12)
CADa 4 13,397 (4) 13,397 (4) 4,515 (3)
Cancer 3 5,442 (3) 3,398 (3) 643 (3)
CHF 8 2,002 (8) 1,787 (8) 833 (8)
COPD 3 1,325 (3) 739 (3) 330 (3)
Depression 1 15,000 (1) 15,000 (1) 15,000 (1)
Diabetes 17 15,444 (17) 7,491 (17) 6,213 (17)
ESRD 3 525 (2) 525 (2) 277 (3)
High-risk maternity 3 4,511 (3) 3,877 (3) 2,479 (3)
Rare diseases 1 1,600 (1) 1,600 (1) 1,200 (1)
Other
Breast and lung cancer 1 n/a n/a 928 (1)
Hyperlipidemia 1 39,398 (1) 31,789 (1) 31,174 (1)
aOne respondent furnished limited information on an uncompleted CAD program in addition to full informa-
tion for a completed CAD program. The former is not included here.
CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease;
ESRD, end-stage renal disease; n/a, no response given.
number of enrollees per plan, mean ROI was
2.56:1. Eight respondents reported other fi-
nancial outcomes, with five describing de-
creased costs and three reporting increased
costs.
Utilization outcomes for asthma DM pro-
grams were generally promising, with eight re-
spondents describing decreased hospital and
ER utilization, and two respondents reporting
no change. For programs with quantified uti-
lization decreases, hospital admissions de-
clined by between 3% and 100% (n  5 re-
sponses) and ED visits decreased by between
5% and 87.5% (n  5).
Clinical outcomes were largely positive,
with improvement in appropriate use of
asthma medications reported by seven re-
spondents, decrease in patients with uncon-
trolled asthma by one respondent, and de-
creased days missed from work by another.
One program did not show a change in pre-
valence of asthma medication use. Three 
respondents indicated high or increased
provider satisfaction.
Other diseases. Because fewer than 10 re-
spondents provided detailed information for
DM programs for each of the other medical
conditions, in-depth descriptions of the survey
results are not provided here for these condi-
tions. As summarized in Table 3, positive out-
comes were reported for at least some DM pro-
grams for most diseases.
Improvement and future directions of disease
management programs
Most respondents who answered how they
saw their organization’s investment in DM
changing over the next three years anticipated
that it would increase (21 of 24 respondents;
88%); three (13%) reported that they did not
know the direction of future DM investment.
No respondents anticipated decreasing DM in-
vestment. Considering DM programs not yet
offered, the three highest priority DM pro-
grams for respondents’ organizations to de-
velop and implement in future were for lower
back pain, CAD, and depression.
Another section of the questionnaire asked
which of six Internet applications health plans
already used in DM programs and which they
intended to implement over the next 2 years.
The questionnaire did not have a separate op-
tion for “do not intend to implement,” so no
answer was taken to signify no intention to im-
plement. Figure 3 shows that online patient re-
minders, online health risk assessments, and
Web-based patient education were most often
identified for future implementation. Consid-
ering both current offerings and future imple-
mentation, the most prevalent applications
were Web-based patient education, online
health risk assessments, and Web-based clini-
cal guidelines. Health plans that already used
Internet applications did not experience high
satisfaction with these tools; mean scores for
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TABLE 3. OUTCOMES OF DISEASE MANAGEMENT PROGRAMS FOR NINE MEDICAL CONDITIONS
No. of respondents reporting positive outcomesa/no. reporting detailed outcomes results
Condition ROI Financial Utilization Clinical Provider relations
CAD 2/2 2/4 1/1 4/4 1/1
Cancer 2/2 2/2 1/1 n/a n/a
CHF 3/3 4/7 4/5 3/3 1/1
COPD n/a 1/1 n/a 1/1 1/1
Depression n/a n/a n/a 0/1 n/a
ESRD 0/2 2/2 1/2 1/1 0/1
High-risk maternity n/a 1/1 2/3 2/2 n/a
Hyperlipidemia n/a n/a 1/1 1/1 n/a
Rare diseases 1/1 1/1 n/a n/a n/a
aRemaining respondents reported no improvement or negative outcomes.
ROI, return on investment; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic ob-
structive pulmonary disease; ESRD, end-stage renal disease; n/a, not measured or no response given.
satisfaction with these six applications ranged
from 2.4 (for online patient reminders) to 3.7
(remote monitoring) on a scale from 1 (not sat-
isfied) to 5 (very satisfied).
Respondents were asked to rate the impor-
tance of each of 10 potential barriers to ex-
panding DM programs in the future; 23–25 re-
sponses were obtained for each barrier. The
three obstacles most frequently identified as
being important or very important were lim-
ited financial resources to invest in DM (17 of
25 responses; 68%), lack of demonstrated clin-
ical and/or financial outcomes (14/25; 56%),
and lack of patient interest in participation or
follow through (13/25; 52%). The three barri-
ers most often identified as being unimportant
or of little importance were lack of demand
from employers (16/25; 64%), HIPAA require-
ments (14/24; 58%), and difficulty managing
multiple vendors (13/23; 57%). The remaining
barriers were more often rated as moderately
important: insufficient information, lack of
physician support or “buy-in,” suboptimal
support from senior management, and diffi-
culty coordinating multiple programs.
DISCUSSION
Ability to draw general conclusions from the
results of the Disease Management Outcomes
Consolidation Survey is weakened by several
limitations. Chief among these is the low re-
sponse rate to the survey (less than 10%), re-
sulting in low sample size. Some contacts
stated that they would not provide results
without financial compensation (which was
not available), and others indicated unwilling-
ness to make the requested information public.
An original objective of the survey was to fa-
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FIG. 3. Current and future implementation of Internet applications for disease management (DM) programs by
health plans.
cilitate benchmarking of DM programs, and
some organizations may have chosen not to
participate because they did not wish to be
benchmarked. In addition, the length and com-
plexity of the survey probably dissuaded sev-
eral targeted contacts. Although the cover let-
ter to the survey stated that it should take less
than an hour to complete once the necessary
information was assembled, assembling that
information may have been prohibitively time-
consuming for many. Contacts who did com-
plete and return the survey may have had in-
formation more readily accessible, which
would introduce nonresponse bias if this cor-
related with better program management (ie,
respondents may have had more successful
programs than the average health plan).
In combination with low questionnaire re-
sponse rate, few items were answered by all re-
spondents, further reducing the number of data
points and preventing definitive conclusions
from being reached in many areas. This is par-
ticularly true for the detailed evaluations of
DM program effectiveness, exacerbated by the
difficulty of comparing the “free form” text an-
swers in this section of the survey. The effec-
tiveness section also did not capture possible
reasons for the outcomes reported (eg, why in-
patient admissions increased with one diabetes
DM program). Comparison of results from dif-
ferent respondents would likely have been fa-
cilitated by a more simplified and restrictive
survey instrument.8
Nevertheless, valuable information was ob-
tained reflecting the experience of health plans
covering more than 14 million commercial
members, with over 230,000 enrollees in 57 DM
programs. Some strong themes emerged from
the survey results, including the significant and
increasing role that DM programs play in the
respondents’ organizations. Most respondents
anticipated increasing investment in DM in the
future, which is consistent with the reported
importance of their DM programs to employer
customers. However, just as analysis of survey
results was hampered by differences in the
types of outcomes measured and reported by
respondents, respondents also identified lack
of standardized methodology as a major bar-
rier to their in-house program evaluations. This
constitutes a problem for commercial health
plans; most respondents indicated that cus-
tomers at least occasionally request proof of the
financial benefit of their programs. Differences
in outcome measurements impair the ability of
health plans to benchmark the performance of
their DM programs against others. These find-
ings support calls for work and consensus on
a standardized framework for evaluating out-
comes of DM programs.1,9
Improving clinical outcomes appeared to be
the highest priority for DM programs, consid-
ered very important by more survey respon-
dents than either cost or utilization control.
This result indicates industry accord with the
first guiding principle of the American Heart
Association’s policy recommendations for DM,
namely that its main goal should be to improve
quality of care and patient outcomes, empha-
sizing the overall benefits derived from DM
rather than only reduced health care expendi-
tures.9 Other authors have echoed the princi-
ple that the rationale for DM programs should
be based on their effectiveness and value, like
other medical interventions.10
One proposed method to measure the over-
all value of different DM programs and com-
pare them with other medical interventions is
to express clinical benefit in terms of quality-
adjusted life-years (QALYs), allowing cal-
culation of cost-utility ratios (ie, cost per
QALY).11,12 For example, a meta-analysis of
randomized controlled trials (RCTs) of DM
programs for depression reported cost-utility
ratios between $9051/QALY and $49,500/
QALY,13 below the threshold of $50,000/QALY
that has been frequently cited since 1982 as ac-
ceptably cost-effective, and highly cost-effec-
tive by today’s standards.14 However, cost-
utility analysis has not yet achieved the promi-
nence in DM that it has in other branches of
medical outcomes research.
Indeed, for commercial health plans that
must justify their DM programs to customers,
ROI remains a key metric despite methodolog-
ical criticisms leveled against it.15,16 Of the five
ROI values provided by survey respondents for
diabetes and asthma programs, four indicated
cost savings of similar magnitude to ROI for
DM programs targeting these conditions re-
ported in the recent literature,17–19 but one sug-
gested increased costs. Given the diversity of
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patient populations, program designs and an-
alytical methods used by responding health
plans, such variation in financial results is not
unexpected. Future efforts should focus on
identifying what factors (eg, time since imple-
mentation) most strongly predict why some
DM programs show cost savings while others
increase expenditures.
Only one responding health plan reported
using the “gold standard” RCT design to eval-
uate its DM program. Because of its conve-
nience, it is not surprising that the pre-post de-
sign was most often employed. However, this
method is not as scientifically rigorous as those
that use randomization or control groups.20,21
The DMAA’s Consensus Statement on assess-
ing DM outcomes recommends randomized
controlled designs whenever possible; when
this is not practical, a control group is prefer-
able to a pre-post design.22 Use of the next
most frequently reported method, historical
controls, has the advantage of reducing the
problem of regression to the mean15; however,
it remains susceptible to changes in external
factors unrelated to DM program effects.20 The
CBO critique of the financial benefit of DM
programs highlighted the limitations of out-
comes comparators other than randomized
control groups.4 More widespread use of RCTs
such as the “Women Take PRIDE” DM pro-
gram, which conservatively estimated that
savings exceeded program costs by 5:1 for pa-
tients with heart disease,23 would presumably
go a long way to addressing CBO concerns
(this study was apparently not considered in
the CBO review).
Non-outcomes results of the Disease Man-
agement Outcomes Consolidation Survey also
were informative. Although satisfaction with
Internet-based applications was moderate,
many respondents planned to add more of
these tools in the near future. This finding sup-
ports predictions that the use of information
management technologies in DM programs
will continue to grow.24,25 Additional research
is warranted to quantify the costs and benefits
of these tools.
Ongoing Medicare DM demonstration proj-
ects are expected to provide considerable data
on the financial, utilization and clinical bene-
fits of DM programs.26 Reduced utilization al-
ready has been demonstrated to offset program
costs in a RCT of a multi-disease DM program
for Medicare Plus Choice enrollees.27 There is
great scope, however, for commercial health
plans to contribute valid evidence that can be
compared among DM programs by heeding
recommendations of recently issued guide-
lines when they conduct program evalua-
tions.12,20–22,28
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